Search

Introducción: el síndrome linfocutáneo es una forma clínica muy característica de linfangitis, que se presenta con nódulos inflamatorios subcutáneos que siguen un trayecto. Se han descrito múltiples patologías infecciosas que podrían tener esta presentación clínica y su enfoque diagnóstico es clave para un tratamiento acertado. Métodos: se realizó una búsqueda en PubMed MEDLINE y, posteriormente, una revi­sión narrativa describiendo las diferentes etiologías infecciosas del síndrome linfocutáneo. Resultados: el síndrome linfocutáneo puede tener múltiples causas, dentro de las cuales se encuentran infecciones micóticas, bacterianas, por micobacterias típicas o atípicas, y parásitos, siendo Sporothrix schenckii, Nocardia bra­siliensis, Mycobacterium marinum y Leishmania sp. los agentes más frecuentemente asociados. Para determinar su etiología, es necesario considerar aspectos en la anamnesis (procedencia, ocupación, tiempo de evolución, an­tecedente de trauma), semiología de las lesiones, sintomatología asociada y, en muchos casos, confirmación diag­nóstica con biopsias de piel, cultivo o tinción de Gram, u otros. Su tratamiento debe ser dirigido y, generalmente, debido al compromiso de trayectos linfáticos, se extiende por más tiempo respecto a las infecciones localizadas. Conclusiones: cuando nos enfrentamos a un paciente con hallazgos sugestivos de síndrome linfocutáneo, de­bemos considerar múltiples etiologías infecciosas. Con el fin de hacer más sencillo el enfoque diagnóstico, propo­nemos clasificar los agentes causales en 4 grandes grupos: infecciones micóticas, bacterianas, por micobacterias y parasitarias.

Given that the COVID-19 era has changed the behavior of all individuals, and since previous reports about its possible impact on atopic dermatitis (AD) patients remained speculative, in this survey we aimed to explore the real impact of COVID-19 among AD patients. All participants provided verbal consent prior to completing the survey. A 37-question web-based survey with no personal identifiers was sent to 212 previously identified AD patients. Itching, sleep disturbances, SARS-CoV-2, illness cost, economic dependence, monthly income, and monthly investment in AD before and during the pandemic, were all included in the analysis. A response rate of 73.1% was obtained. The mean age of participants was 30 years-old, and 57% were women. Around 75% reported AD worsening, and 59.4% of the patients reported sleep problems. Uncertainty, anxiety, and pessimism were frequent during the pandemic. Only 1.3% tested positive for SARS-CoV-2, and it was only significantly associated with comorbidities (p=0.03; Chi2 Test). A significant difference was found in economic dependence and monthly income when compared between before and during the pandemic. This study provides probably the best possible assessment of the clinical, social, and economic effects of the pandemic on patients with an already proven diagnosis of AD.

Introduction: Paraneoplastic pemphigus is an autoimmune disease associated with an underlying tumor. Several cases have been reported as unusual pemphigus vulgaris, erythema multiforme, or paraneoplastic bullous disease,1 but the incidence of the condition is unknown.2 Response to treatment is generally poor, with significant morbidity and mortality. This condition is clinically characterized by severe mucositis and polymorphic blistering skin eruptions, and histologically by acantholysis, keratinocyte necrosis, and interface dermatitis.3 Immunoprecipitation and immunoblot testing detect autoantibodies against desmosomal polypeptides.4 We describe a case of paraneoplastic pemphigus associated with an abdominal inflammatory myofibroblastic tumor in a 7-year-old girl.